Neil Bifulco

899 total citations
8 papers, 472 citations indexed

About

Neil Bifulco is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Neil Bifulco has authored 8 papers receiving a total of 472 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Molecular Biology, 3 papers in Oncology and 2 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Neil Bifulco's work include Fibroblast Growth Factor Research (4 papers), Kruppel-like factors research (3 papers) and Epigenetics and DNA Methylation (3 papers). Neil Bifulco is often cited by papers focused on Fibroblast Growth Factor Research (4 papers), Kruppel-like factors research (3 papers) and Epigenetics and DNA Methylation (3 papers). Neil Bifulco collaborates with scholars based in United States and South Korea. Neil Bifulco's co-authors include Timothy J. Guzi, Natasja Brooijmans, Nooreen Rubin, Christoph Lengauer, Michael P. Sheets, Joseph L. Kim, Margit Hagel, Nancy E. Kohl, Weifan Weng and Christopher Winter and has published in prestigious journals such as Cancer Research, Journal of Hepatology and Cancer Discovery.

In The Last Decade

Neil Bifulco

8 papers receiving 465 citations

Peers

Neil Bifulco

MB

ONCOL

CR

HEPAT

VIROL

Albert Liclican United States

Sheri Rogers United States

Shitao Zou China

Zhenqing Feng China

Mona Ahmed Egypt

Lindsay Stimson United Kingdom

Birgit Zech Germany

Tanya Watanabe United States

Eleanor Dagostino United States

Guus M. Bol Netherlands

Albert Liclican United States

Neil Bifulco

254 ×0.8

MB

77 ×0.9

ONCOL

43 ×0.7

CR

9 ×0.2

HEPAT

63 ×1.1

VIROL

Citations per year, relative to Neil Bifulco Neil Bifulco (= 1×) peers Albert Liclican

Countries citing papers authored by Neil Bifulco

Since Specialization

Citations

This map shows the geographic impact of Neil Bifulco's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Neil Bifulco with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Neil Bifulco more than expected).

Fields of papers citing papers by Neil Bifulco

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Neil Bifulco. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Neil Bifulco. The network helps show where Neil Bifulco may publish in the future.

Co-authorship network of co-authors of Neil Bifulco

This figure shows the co-authorship network connecting the top 25 collaborators of Neil Bifulco. A scholar is included among the top collaborators of Neil Bifulco based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Neil Bifulco. Neil Bifulco is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

1.

House, Nealia C., Karen J. Ho, Hsin‐Jung Wu, et al.. (2023). Abstract P6-10-07: CDK2 inhibition with BLU-222 in combination with ribociclib demonstrates robust antitumor activity in pre-clinical models of CDK4/6 inhibitor-naïve and -resistant HR+/HER2- breast cancer. Cancer Research. 83(5_Supplement). P6–10. 8 indexed citations

2.

House, Nealia C., Jian Guo, Ruduan Wang, et al.. (2022). Abstract 2306: BLU-222, an investigational, potent, and selective CDK2 inhibitor, demonstrated robust antitumor activity in CCNE1-amplified ovarian cancer models. Cancer Research. 82(12_Supplement). 2306–2306. 8 indexed citations

3.

Hatlen, Megan, Oleg Schmidt-Kittler, Cori Ann Sherwin, et al.. (2019). Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma. Cancer Discovery. 9(12). 1686–1695. 90 indexed citations

4.

Hagel, Margit, Chandra Miduturu, Michael P. Sheets, et al.. (2015). First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway. Cancer Discovery. 5(4). 424–437. 247 indexed citations

5.

Hoeflich, Klaus P., Margit Hagel, Chandra Miduturu, et al.. (2015). O048 : First selective small molecule inhibitor of FGFR4 for the treatment of hepatocellular carcinomas with an activated FGFR4 signaling pathway. Journal of Hepatology. 62. S215–S216. 1 indexed citations

6.

Hagel, Margit, Chandra Miduturu, Weifan Weng, et al.. (2014). Abstract LB-324: First isoform selective inhibitor of FGFR4 for the treatment of genomically defined patients with hepatocellular carcinoma. Cancer Research. 74(19_Supplement). LB–324. 4 indexed citations

7.

Kazmierski, Wieslaw M., Neil Bifulco, Hanbiao Yang, et al.. (2003). Recent progress in discovery of small-molecule CCR5 chemokine receptor ligands as HIV-1 inhibitors. Bioorganic & Medicinal Chemistry. 11(13). 2663–2676. 85 indexed citations

8.

Milkiewicz, Karen L., et al.. (2000). The design, synthesis and activity of non-ATP competitive inhibitors of pp60c-src tyrosine kinase. Part 2: Hydroxyindole derivatives. Bioorganic & Medicinal Chemistry Letters. 10(5). 483–486. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact